1. Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial
- Author
-
Howard B Mayer, Juan Sierra-Madero, Jayvant Heera, Judith A. Aberg, Natasa Rajicic, Hernan Valdez, G. Di Perri, Adriano Lazzarin, A. MacInnes, James Goodrich, Macinnes, A., Lazzarin, Adriano, Di Perri, G., Sierra Madero, J. G., Aberg, J., Heera, J., Rajicic, N., Goodrich, J., Mayer, H., and Valdez, H.
- Subjects
Cyclopropanes ,Male ,isolation /&/ purification ,Blood lipids ,HIV Infections ,Pharmacology ,Gastroenterology ,antagonists /&/ inhibitors/metabolism ,Maraviroc ,chemistry.chemical_compound ,Receptors ,Pharmacology (medical) ,administration /&/ dosage ,Lamivudine ,Infectious Diseases ,Cholesterol ,Alkynes ,CCR5 Receptor Antagonists ,lipids (amino acids, peptides, and proteins) ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Efavirenz ,Receptors, CCR5 ,Anti-HIV Agents ,blood/drug therapy/virology ,Zidovudine ,blood ,Cyclohexanes ,Internal medicine ,Post-hoc analysis ,medicine ,Humans ,National Cholesterol Education Program ,Triglycerides ,Dyslipidemias ,Chi-Square Distribution ,business.industry ,Triazoles ,Lipid Metabolism ,Benzoxazines ,chemistry ,drug effects ,HIV-1 ,business ,CCR5 ,Adult, Anti-HIV Agents ,administration /&/ dosage, Benzoxazines ,administration /&/ dosage, Chi-Square Distribution, Cholesterol ,blood, Cyclohexanes ,administration /&/ dosage, Dyslipidemias ,blood/drug therapy/virology, Female, HIV Infections ,blood/drug therapy/virology, HIV-1 ,isolation /&/ purification, Humans, Lipid Metabolism ,drug effects, Male, Receptors ,antagonists /&/ inhibitors/metabolism, Triazoles ,administration /&/ dosage, Triglycerides - Abstract
"We investigated the effects of maraviroc, the first approved CC-chemokine receptor 5 (CCR5) antagonist, on blood lipids in a post hoc analysis of the phase 3 MERIT study in treatment-naive patients. Methods: Patients received maraviroc 300 mg twice daily (n = 360) or efavirenz 600 mg once daily (n = 361), both in combination with zidovudine\/lamivudine, for up to 96 weeks. Baseline and on-treatment lipid profiles were analyzed according to National Cholesterol Education Program (NCEP) thresholds. Results: Baseline characteristics and lipid profiles were comparable between groups. Among patients with total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) below NCEP treatment thresholds at baseline, significantly more efavirenz- than maraviroc-treated patients exceeded those thresholds at 96 weeks (TC: 35% [74\/209] vs 11% [20\/188], P < .0001; LDL-c: 23% [47\/197] vs 8% [15\/183], P < .0001). Among patients exceeding NCEP thresholds at baseline, significantly more efavirenz- than maraviroc-treated patients exceeded the thresholds at 96 weeks (TC: 83% [24\/29] vs 50% [17\/34], P = .0084; LDL-c: 86% [19\/22] vs 55% [16\/29], P = .0314). Of those with baseline high-density lipoprotein cholesterol (HDL-c)
- Published
- 2011